AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03575559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual planning
Description: Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Study NCT03575559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative planning
Description: Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
Study NCT03575559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and motivation treatment
Description: Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
Study NCT03575559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and motivation treatment
Description: Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
Study NCT03705351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
Study NCT03705351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will be given temozolomide according to routine treatment dosing and schedule.
Study NCT03705351 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will be given radiation therapy according to routine treatment dosing and schedule.
Study NCT02415166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA VACCINE
Description: THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
Study NCT02415166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl-saline placebo
Description: placebo
Study NCT02917200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral route
Study NCT02917200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route
Study NCT02917200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route
Study NCT00348777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Study NCT00348777 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 3 days access to watering place at 6 months
Description: access to watering place for movement in swimming pool, sauna and hammam.
Study NCT02818452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28XF
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
Study NCT02917200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative control
Description: Oral route
Study NCT02917200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative control
Description: Oral route
Study NCT02655354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Study NCT02655354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Elements
Study NCT02655354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Anti-depressant
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Sleep medication
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Sleep medication
Study NCT02655354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Sleep medication
Study NCT01768962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% Gel - Vaginal
Description: Vaginal application
Study NCT01768962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% gel - Rectal
Description: Rectal application
Study NCT02818452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study NCT02818452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot cereal
Study NCT02363218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
Study NCT00406367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection
Study NCT00406367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
Study NCT00933023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 1%hydrocortisone topical once daily for 8 weeks
Study NCT00933023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Betamethasone 0.1% topical once daily for 8weeks
Study NCT04022538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement
Description: Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~* The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material.
Study NCT04022538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation
Description: Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material.
Study NCT00006721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given orally
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT00006721 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab
Description: Given IV
Study NCT00215982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
Study NCT04387916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
Study NCT04593771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Study NCT00215982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
Study NCT00215982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
Study NCT01018888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auro KPro (Keratoprosthesis)
Description: Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
Study NCT03980795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
Study NCT02755467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP laser
Description: Dual Wavelength Laser Emitting 532 nm Laser Energy
Study NCT04396262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: HTD-blueberry beverage with white bread.
Study NCT04396262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Sweetened water with white bread as a control.
Study NCT04021914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnChroma glasses
Description: Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
Study NCT01915602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
Study NCT01915602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006)
Description: Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
Study NCT03403140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week
Study NCT02375360 — intervention group
Intervention type: OTHER
Intervention: Oral immunotherapy
Study NCT04593771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Study NCT04767269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cuminum Cyminum
Description: Cuminum Cyminum mouthwash in chronic gingivitis patients
Study NCT04767269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal Mouthwash
Description: herbal mouthwash in chronic gingivitis patients
Study NCT01038583 — intervention group
Intervention type: DRUG
Intervention: 100 mg enteric-coated aspirin
Description: 100 mg enteric-coated aspirin, taken daily
Study NCT03873714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Vantage Embolization Device with Shield Technology™
Description: Pipeline™ Vantage Embolization Device with Shield Technology™
Study NCT01038583 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: 100 mg enteric-coated placebo
Study NCT04559295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
Study NCT02102490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04345471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg
Description: once daily dosing for 8 weeks
Study NCT04345471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg
Description: once daily dosing for 8 weeks
Study NCT04345471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily dosing for 8 weeks
Study NCT01114113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pancelipase/placebo
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.
Study NCT01114113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pancelipase/placebo
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.
Study NCT01114113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
Study NCT01114113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule
Study NCT01114113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: SmartPill capsule
Study NCT01114113 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SmartPill capsule
Description: SmartPill capsule
Study NCT02476552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Capsules (Labeled)
Description: Single 300 mg dose of niraparib
Study NCT02476552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib IV (Labeled)
Description: Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)
Study NCT02476552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Capsules (Unlabeled)
Description: Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
Study NCT04476732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraben-free skincare product
Description: Paraben-free lotion will be applied twice a day for one week.
Study NCT04476732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraben-containing skincare product
Description: Paraben-containing lotion will be applied twice a day for one week.
Study NCT04561310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post facilitation stretch
Description: Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session
Study NCT04561310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active release technique
Description: Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session
Study NCT02480010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
Study NCT02141178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine